NCMP-02. MYASTHENIA GRAVIS INDUCED BY AVELUMAB

Monoclonal antibodies targeting PD- 1 (nivolumab and pembrolizumab) and PD-L1 (avelumab, atezolizumab, and durvalumab) are FDA approved for the treatment of metastatic cancers. Immune-related adverse events (irAEs) are autoimmune diseases which occur following treatment with PD-1 and PD-L1 inhibitor...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Yuen, Carlen, Fleming, Gini, Soliven, Betty, Myers, Michael, Rezania, Kourosh
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Neurological Complications of Cancer and Cancer Therapy
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847032/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.748
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki